Medication info

Myungmoon Linagliptin Duo Tablet 2.5/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Bright yellow, double-convex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTPX6)
Approval status
Expired

MFDS item code 201905076 · Approved 2019.07.19

This product's status changed to Expired on 2024.07.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 2.5/500 mg twice daily, 1 tablet per dose, and may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take as the initial dose the same doses of linagliptin and metformin they were previously taking. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to be a dose similar to the patient's existing metformin dose, together with linagliptin 2.5 mg twice daily (total daily dose 5 mg). When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral hypoglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this drug, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used as an adjunct for adults with type 2 diabetes when glycemic control is difficult with diet and exercise alone. It is especially administered to patients who have not previously received any diabetes medication and find it difficult to manage blood sugar on their own. It can be used instead of the combination therapy of linagliptin and metformin and can be administered together with insulin when blood sugar control is insufficient after insulin and metformin combination therapy. Lastly, if blood sugar is not controlled even with the maximum dose of metformin and empagliflozin, it can be co-administered with empagliflozin. This medication improves blood sugar control in conjunction with various treatment options.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 2.5/500 mg twice daily, 1 tablet per dose, and may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take as the initial dose the same doses of linagliptin and metformin they were previously taking. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to be a dose similar to the patient's existing metformin dose, together with linagliptin 2.5 mg twice daily (total daily dose 5 mg). When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral hypoglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this drug, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication helps in controlling blood sugar. However, since a serious side effect known as lactic acidosis can occur, it should not be used in patients with impaired kidney function or severe liver dysfunction. Additionally, patients with serious cardiac or pulmonary impairment such as acute myocardial infarction, shock, or heart failure should not take this medication. Women who are pregnant or breastfeeding should also avoid this medication. During treatment, symptoms of hypoglycemia may occur, so it is important to carefully monitor blood sugar changes, especially if taking insulin or sulfonylureas concurrently. If symptoms such as abdominal pain, myalgia, weakness, or shortness of breath develop, consult a doctor immediately. As this medication is excreted through the kidneys, regular kidney function tests should be conducted and the medication should be temporarily discontinued if kidney function deteriorates sharply. If iodine contrast is used during radiology tests, the medication should be stopped before and after the tests, and resumed only after confirming kidney function. In the case of impending surgery, the medication should also be discontinued 48 hours prior to the surgery and resumed after kidney function has recovered post-surgery. This medication may cause side effects such as gastrointestinal disturbances, diarrhea, and loss of appetite, and there may be a risk of vitamin B12 deficiency with long-term use, necessitating regular exams. Elderly patients are particularly prone to decreased kidney function, so dose adjustment and regular kidney function monitoring are important. This medication may interact with other drugs, so notify the doctor or pharmacist of any other medications being taken. Alcohol should be avoided during the course of treatment, and the medication should not be used in cases of acute alcohol intoxication. If an overdose occurs, seek proper treatment immediately at a hospital. Finally, this medication has not been proven safe or effective in children, so it is advisable not to use it in this group.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of Vitamin B12, hypoglycemia, taste disorder, cough, appetite loss, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, formation of oral ulcers, abnormal liver function test, hepatitis, pruritus, erythema, rash, dermatitis herpetiformis, arthralgia accompanied by severe and debilitating symptoms, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, appetite loss, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, stomach cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, renal transplant failure, anxiety, affective disorders, insomnia, depression, contusions, bone contusion, concussion, bone fracture, angina, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid enlargement, anemia, itching, hypertension, benign prostatic hyperplasia, vitreous hemorrhage, delirium, nocturia, dermatitis, osteoarthritis, limb pain, dizziness, sensory loss, drowsiness, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorder, epistaxis, male pattern baldness, hyperhidrosis, hair loss, unstable angina, vocal cord polyp, myelodysplastic syndrome, ligament sprain, flank pain, dyspepsia, rectal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, increased serum creatinine, facial swelling, hyperthermia, back pain, rotator cuff syndrome, headache, subdural effusion, corneal abrasion, fall, upper limb fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to store it at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness. Storing it this way will prevent the medication from deteriorating or losing its efficacy.

Appearance and packaging

Appearance

Bright yellow, double-convex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTPX6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.